Regulation of Id-1 Gene Expression in Aggressive Breast Cancer and Glioblastoma Cells Using Cannabinoid Compounds
AbstractWe investigated Id-1 gene expression in aggressive breast cancer cells and glioblastoma cells, and compared Id-1 expression in control cells with cells treated with one of the cannabinoid compounds, cannabidiol (CBD) or tetrahydrocannabinol (THC). The tumor cells were treated with CBD or THC, and the control group was treated with ethanol. After 2-3 days of treatment, cells were harvested and proteins extracted from them. Following protein electrophoresis, Western blot technique was used to analyse the expression of Id-1 protein derived from the samples. Using a rabbit monoclonal anti-human Id-1 antibody, and a goat anti-rabbit HRP as a secondary antibody, the intensities of the bands produced following film exposure were used to compare drug-treated cells with controls. Id-1 gene expression was decreased in tumor cells treated with cannabinoid compounds. We also aimed to visualize tumor cell migration through a living tissue and to determine the possible inhibition of migration upon treatment with CBD. Tumor cell migration through a living tissue was studied by placing GFP-labelled glioblastoma cells on top of Sprague-Dawley rat brain slices. Migration was studied using the Carl-Zeis cell monitor. Glioblastoma cells placed on brain slices of Sprague-Dawley rats were found to migrate through the tissue to the other side of the slice. The morphology of glioblastoma cells was also found to be modified upon treatment (changes in cell-to-cell contacts). This study shows that Id-1 downregulation strongly correlates with a reduced tumor aggressiveness and that Id-1 might represent a potent therapeutic target for breast cancer and glioblastoma.
. Braun S, Harbeck N. Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention. Expert Rev Mol Med 2001; 3:1-14
. Inhibitor of DNA binding-1, dominant negative helix-loop-helix protein. Available on: http://www.genecards.org/cgi-bin/carddisp.pl?gene=ID1
. Fong S, Itahana Y, Sumida T, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 2003; 100: 13543-8
. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74:129-80
. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547-50
. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278:989-99
. Training: Laboratory animal care and use. Available at: www.iacuc.org/guidelines.htm
. Desprez PY, Lin CQ, Thomasset N, Sympson CJ, Bissell MJ, Campisi J. A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol cell Biol 1998; 18:457-88
. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6(11):2921-7
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.